Skip to main content

Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.

Abstract: Objectives
The study aimed to characterize the pharmacokinetics (PK) of four β-lactams (piperacillin, ceftazidime, cefepime, and meropenem) in patients comedicated with amikacin (AMK), and to confirm the predictive performance of AMK data, obtained from therapeutic drug monitoring (TDM), on these PK, using a population modeling approach.

Design and methods
Serum samples were collected in 88 critically ill septic patients. For each β-lactam, the covariate model was optimized using renal function. Furthermore, predictive performance of AMK concentrations and PK parameters was assessed on β-lactam PK.

A two-compartment model with first-order elimination best fitted the β-lactam data. Results supported the superiority of AMK concentrations, over renal function and AMK PK parameters, to assess the β-lactam PK.

The study confirmed the significant link between the exposure to AMK and to β-lactams, and presented population models able to guide β-lactam dosage adjustments using renal biomarkers or TDM-related aminoglycoside data.

Full Reference: Delattre, Isabelle K., Flora T. Musuamba, Philippe Jacqmin, Fabio S. Taccone, Pierre-Francois Laterre, Roger K. Verbeeck, Frederique Jacobs, and Pierre Wallemacq. “Population Pharmacokinetics of Four Beta-Lactams in Critically Ill Septic Patients Comedicated with Amikacin.” Clinical Biochemistry 45, no. 10–11 (July 2012): 780–86. doi:10.1016/j.clinbiochem.2012.03.030.

Link to full text:

How can we help you?